Clinical Experience of Revision of Metal on Metal Hip Arthroplasty for Aseptic Lymphocyte Dominated Vasculitis Associated Lesions (Alval)
Citations Over TimeTop 10% of 2011 papers
Abstract
There has been growing concern regarding the systemic and local effects of metal ions released from metal-on-metal hip resurfacings and total hip replacements, including the development of aseptic lymphocyte dominated vasculitis associated lesions (ALVAL). We describe our experience of treating 13 patients with failed metal on metal bearing hip prostheses secondary to this condition. Hip revision occurred at mean of 45 months following primary surgery. Groin pain was present in all patients. Other common features included large bursal swelling and mechanical symptoms. 3 patients developed their symptoms immediately postoperatively. The mean time to presentation was 21 months. Radiographic abnormalities noted included 3 patients with cup loosening and 2 patients with neck thinning. The mean cup inclination was 52 degrees. Surgical findings included bursal swellings and creamy brown fluid. Osteolysis was rarely seen. 12 revisions were achieved with primary implants and all patients had immediate symptomatic improvement. One patient was left with a pseudoarthrosis due to extensive soft tissue destruction. Diagnosis of ALVAL was confirmed histologically. The diagnosis of ALVAL should be considered in patients with unexplained pain from a metal on metal bearing hip arthroplasty. Surgical findings are typical and symptoms tend to resolve reliably following conversion to an alternative bearing surface.
Related Papers
- → Hip resurfacing arthroplasty(2010)10 cited
- → How Easy is it to Revise a Failed Resurfacing of the Hip?(2008)1 cited
- BIRMINGHAM HIP RESURFACING IN THE FEMALE PATIENT OVER THE AGE OF 50 YEARS IS A SAFE AND RELIABLE FORM OF HIP ARTHROPLASTY(2010)
- → Trends in activity levels a year after hip resurfacing arthroplasty(2017)
- → Hip Resurfacing Arthroplasty Failure. Conversion to Total Hip is it a Favorable Solution with Satisfactory Outcomes?(2022)